Skip to Main Content

Paper Details

Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
JAMA
34
2021
Author NameAffiliation
Bruce E LandonHarvard Medical School
  • 1 - 1

Datasets

Release 1.2